Metraipolis › archive › dc_c7f58a42fa66

161 Tb-PSMA radioligand therapy in prostate cancer: current evidence and future perspectives — Europe PMC PMID:41613555

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41613555
DOI
10.3389/fonc.2025.1743628
License (as archived)
solo-consultazione
Archived
2026-10-07T14:11:09.260Z
SHA-256 of the archived text
903f293c069340aece7494729053d4bcab2884cf2003e072fd6e61a111a3cf04
Stable URL of this page
https://metraipolis.com/documento/dc_c7f58a42fa66

How to cite

161 Tb-PSMA radioligand therapy in prostate cancer: current evidence and future perspectives — Europe PMC PMID:41613555 — Europe PMC (en), https://europepmc.org/article/MED/41613555 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c7f58a42fa66 (Metraipolis archive dc_c7f58a42fa66, sha256 903f293c069340aece7494729053d4bcab2884cf2003e072fd6e61a111a3cf04)
BibTeX
@misc{dcc7f58a42fa66,
  title = {161 Tb-PSMA radioligand therapy in prostate cancer: current evidence and future perspectives — Europe PMC PMID:41613555},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41613555},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c7f58a42fa66; sha256 903f293c069340aece7494729053d4bcab2884cf2003e072fd6e61a111a3cf04},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41613555. Agents can read the archived copy with the MCP tool read_document.